## In the Figures

Please insert new Figure 14 at the end of the figures.

## In the Claims

Please cancel Claims 164-201 (all of the pending claims) without prejudice.

Applicants will pursue these claims, or claims similarly directed to the subject matter thereof, by way of one or more continuation applications.

## Please add the following claims.

--Claim 202 (new). A purified and isolated DNA molecule capable of propagation in *E.coli* comprising a nucleotide sequence that encodes human cystic fibrosis transmembrane conductance regulator ("CFTR") protein, said nucleotide sequence differing from a wild type CFTR-encoding nucleotide sequence by the presence of one or more point mutations in the region comprising nucleotide positions 908 to 936.

Claim 203 (new). A DNA molecule according to Claim 202 containing a single point mutation.

Claim 204 (new). A DNA molecule according to Claim 202 containing a T to C mutation at nucleotide position 936.

Claim 205 (new). A DNA molecule according to Claim 202 wherein said CFTR-encoding nucleotide sequence is cDNA.

Claim 206 (new). A purified and isolated DNA molecule capable of propagation in *E. coli* comprising:

a first nucleotide sequence that encodes a wild type human cystic fibrosis transmembrane conductance regulator ("CFTR") protein; and

a second nucleotide sequence, whereby said second sequence disrupts expression of CFTR fragments toxic to E. coli, said second sequence being located downstream from nucleotide position 907 of said CFTR-encoding sequence.

Claim 207 (new). A DNA molecule according to Claim 206 wherein said second sequence is a sequence capable of being spliced from CFTR primary RNA transcript when expressed in an eukaryotic cell.

Claim 208 (new). A DNA molecule according to Claim 206 wherein said second sequence comprises a stop codon.

Claim 209 (new). A DNA molecule according to Claim 206 wherein said second sequence disrupts the translational reading frame of said encoding DNA.

Claim 210 (new). A DNA molecule according to Claim 206 wherein said second sequence is placed between nucleotides 1716 and 1717 of said encoding DNA.

Claim 211 (new). A DNA molecule according to Claim 206 wherein said CFTR-encoding sequence is cDNA.

Claim 212 (new). A plasmid comprising a DNA molecule according to Claim 202.

Claim 213 (new). A plasmid comprising a DNA molecule according to Claim 206.

Claim 214 (new). A host *E.coli* cell comprising a plasmid according to Claim 212.

Claim 215 (new). A host *E.coli* cell comprising a plasmid according to Claim 213.

Claim 216 (new). A purified and isolated DNA molecule capable of propagation in *E. coli* comprising:

- (1) a nucleotide sequence that encodes wild-type human human cystic fibrosis transmembrane conductance regulator ("CFTR") protein, and
- (2) an origin of replication permits maintenance of said DNA molecule at low copy number in a host *E. coli* cell.

Claim 217 (new). A DNA molecule according to Claim 216 wherein said origin of replication permits maintenance of said DNA molecule at about 25 copies or less in a host *E. coli* cell.

Claim 218 (new). A DNA molecule according to Claim 217 consisting essentially of the plasmid pSC-CFTR2.

Claim 219 (new). A host *E. coli* cell comprising a DNA molecule according to Claim 216.

Claim 220 (new). A host E. coli cell according to Claim 219 identified as pSC-CFTR2/AG1 deposited with the American Type Culture Collection as ATCC 68244.

Claim 221 (new). A host *E. coli* cell comprising a low copy number of nucleotide sequences that encode human cystic fibrosis transmembrane conductance regulator ("CFTR") protein.

Claim 222 (new). An RNA molecule complementary to the encoding nucleotide sequence of a DNA molecule according to Claim 202.

Claim 223 (new). An RNA molecule complementary to the first and second nucleotide sequences of a DNA molecule according to Claim 206.--